Your browser doesn't support javascript.
loading
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster, David I; Mackinnon, A Craig; Ronen, Natali; Mejbel, Haider A; Harada, Shuko; Michal, Michael; Suster, Saul.
Afiliação
  • Suster DI; Department of Pathology, Rutgers University, New Jersey Medical School, Newark, NJ.
  • Mackinnon AC; Department of Pathology, University of Alabama, Birmingham, AL.
  • Ronen N; Department of Pathology, Medical College of Wisconsin, Milwaukee, WI.
  • Mejbel HA; Department of Pathology, Emory University School of Medicine, Atlanta, GA.
  • Harada S; Department of Pathology, University of Alabama, Birmingham, AL.
  • Michal M; Department of Pathology, Charles University, Faculty of Medicine in Plzen.
  • Suster S; Bioptical Laboratory, Ltd., Plzen, Czech Republic.
Am J Surg Pathol ; 2024 Jul 11.
Article em En | MEDLINE | ID: mdl-38989701
ABSTRACT
A distinctive histological variant of poorly differentiated, sarcomatoid, non-small cell lung carcinoma characterized by a discohesive population of giant tumor cells associated with prominent interstitial inflammatory cell infiltrates is described. The tumors occurred in 7 women and 7 men, 42 to 72 years of age (mean 56 y). They predominantly affected the upper lobes and measured 1.3 to 9 cm in greatest diameter (mean 4.6 cm). The tumor cells were characterized by large pleomorphic nuclei with prominent nucleoli, ample cytoplasm, and frequent abnormal mitoses, and were surrounded by a dense inflammatory cell infiltrate, often associated with emperipolesis. Immunohistochemical stains were positive in the tumor cells for cytokeratin AE1/AE3 and CK8/18 and negative for TTF1, napsin A, p40, and CK5/6. Next-generation sequencing was performed in all cases using the Oncomine Precision Assay; the most common abnormalities found included TP53 mutations (9 cases) and AKT1 amplification (8 cases), followed by KRAS mutations (4 cases) and MAP2K1/2 mutations (4 cases). Clinical follow-up was available in 13 patients. Three patients presented with metastases as the initial manifestation of disease; 8 patients died of their tumors from 6 months to 8 years (mean 2.7 y); 3 patients were alive and well from 4 to 6 years; and 2 patients had metastases when last seen but were lost to follow-up thereafter. The importance of recognizing this distinctive and aggressive variant of non-small cell lung carcinoma lies in avoiding confusion with a sarcoma or other types of malignancy.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Surg Pathol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Surg Pathol Ano de publicação: 2024 Tipo de documento: Article
...